Provided by Tiger Fintech (Singapore) Pte. Ltd.

Meiragtx Holdings Plc

7.26
+0.17002.40%
Pre-market: 7.390.1300+1.79%05:54 EDT
Volume:387.26K
Turnover:2.79M
Market Cap:572.49M
PE:-3.43
High:7.28
Open:7.06
Low:6.86
Close:7.09
Loading ...

Company Profile

Company Name:
Meiragtx Holdings Plc
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
378
Office Location:
450 East 29th Street,14th Floor,New York,New York,United States
Zip Code:
10016
Fax:
- -
Introduction:
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Directors

Name
Position
Alexandria Forbes
President and Chief Executive Officer and Director
Keith R. Harris
Chairman of the Board
Arnold J. Levine
Director
Debra Yu
Director
Ellen Hukkelhoven
Director
Joel S. Marcus
Director
Lord Mendoza
Director
Martin Indyk
Director
Nicole Seligman
Director
Thomas E. Shenk
Director

Shareholders

Name
Position
Alexandria Forbes
President and Chief Executive Officer and Director
Richard Giroux
Chief Operating Officer and Chief Financial Officer
Robert J. Wollin
General Counsel and Secretary
Robert K. Zeldin
Chief Medical Officer
Stuart Naylor
Chief Development Officer